312 related articles for article (PubMed ID: 18642893)
1. Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors.
Huhtiniemi T; Suuronen T; Rinne VM; Wittekindt C; Lahtela-Kakkonen M; Jarho E; Wallén EA; Salminen A; Poso A; Leppänen J
J Med Chem; 2008 Aug; 51(15):4377-80. PubMed ID: 18642893
[TBL] [Abstract][Full Text] [Related]
2. N(epsilon)-thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors.
Kiviranta PH; Suuronen T; Wallén EA; Leppänen J; Tervonen J; Kyrylenko S; Salminen A; Poso A; Jarho EM
J Med Chem; 2009 Apr; 52(7):2153-6. PubMed ID: 19296597
[TBL] [Abstract][Full Text] [Related]
3. Discovering inhibitors of human sirtuin type 2: novel structural scaffolds.
Tervo AJ; Suuronen T; Kyrylenko S; Kuusisto E; Kiviranta PH; Salminen A; Leppänen J; Poso A
J Med Chem; 2006 Nov; 49(24):7239-41. PubMed ID: 17125277
[TBL] [Abstract][Full Text] [Related]
4. N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors.
Kiviranta PH; Leppänen J; Kyrylenko S; Salo HS; Lahtela-Kakkonen M; Tervo AJ; Wittekindt C; Suuronen T; Kuusisto E; Järvinen T; Salminen A; Poso A; Wallén EA
J Med Chem; 2006 Dec; 49(26):7907-11. PubMed ID: 17181175
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
Trapp J; Meier R; Hongwiset D; Kassack MU; Sippl W; Jung M
ChemMedChem; 2007 Oct; 2(10):1419-31. PubMed ID: 17628866
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the binding properties of SIRT2 inhibitors with a N-(3-phenylpropenoyl)-glycine tryptamide backbone.
Kiviranta PH; Salo HS; Leppänen J; Rinne VM; Kyrylenko S; Kuusisto E; Suuronen T; Salminen A; Poso A; Lahtela-Kakkonen M; Wallén EA
Bioorg Med Chem; 2008 Sep; 16(17):8054-62. PubMed ID: 18701307
[TBL] [Abstract][Full Text] [Related]
7. An in silico approach to discovering novel inhibitors of human sirtuin type 2.
Tervo AJ; Kyrylenko S; Niskanen P; Salminen A; Leppänen J; Nyrönen TH; Järvinen T; Poso A
J Med Chem; 2004 Dec; 47(25):6292-8. PubMed ID: 15566299
[TBL] [Abstract][Full Text] [Related]
8. N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors.
Kiviranta PH; Leppänen J; Rinne VM; Suuronen T; Kyrylenko O; Kyrylenko S; Kuusisto E; Tervo AJ; Järvinen T; Salminen A; Poso A; Wallén EA
Bioorg Med Chem Lett; 2007 May; 17(9):2448-51. PubMed ID: 17329104
[TBL] [Abstract][Full Text] [Related]
9. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors.
Mai A; Valente S; Meade S; Carafa V; Tardugno M; Nebbioso A; Galmozzi A; Mitro N; De Fabiani E; Altucci L; Kazantsev A
J Med Chem; 2009 Sep; 52(17):5496-504. PubMed ID: 19663498
[TBL] [Abstract][Full Text] [Related]
10. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing.
Uciechowska U; Schemies J; Neugebauer RC; Huda EM; Schmitt ML; Meier R; Verdin E; Jung M; Sippl W
ChemMedChem; 2008 Dec; 3(12):1965-76. PubMed ID: 18985648
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate.
Asaba T; Suzuki T; Ueda R; Tsumoto H; Nakagawa H; Miyata N
J Am Chem Soc; 2009 May; 131(20):6989-96. PubMed ID: 19413317
[TBL] [Abstract][Full Text] [Related]
12. A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds.
Liu J; Cao R; Yi W; Ma C; Wan Y; Zhou B; Ma L; Song H
Eur J Med Chem; 2009 Apr; 44(4):1773-8. PubMed ID: 18524420
[TBL] [Abstract][Full Text] [Related]
13. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.
Zhang Y; Au Q; Zhang M; Barber JR; Ng SC; Zhang B
Biochem Biophys Res Commun; 2009 Sep; 386(4):729-33. PubMed ID: 19559674
[TBL] [Abstract][Full Text] [Related]
14. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.
Lara E; Mai A; Calvanese V; Altucci L; Lopez-Nieva P; Martinez-Chantar ML; Varela-Rey M; Rotili D; Nebbioso A; Ropero S; Montoya G; Oyarzabal J; Velasco S; Serrano M; Witt M; Villar-Garea A; Imhof A; Mato JM; Esteller M; Fraga MF
Oncogene; 2009 Feb; 28(6):781-91. PubMed ID: 19060927
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode.
Neugebauer RC; Uchiechowska U; Meier R; Hruby H; Valkov V; Verdin E; Sippl W; Jung M
J Med Chem; 2008 Mar; 51(5):1203-13. PubMed ID: 18269226
[TBL] [Abstract][Full Text] [Related]
16. Exploring the newer oxadiazoles as real inhibitors of human SIRT2 in hepatocellular cancer cells.
Dukanya ; Shanmugam MK; Rangappa S; Metri PK; Mohan S; Basappa ; Rangappa KS
Bioorg Med Chem Lett; 2020 Aug; 30(16):127330. PubMed ID: 32631535
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.
Schuetz A; Min J; Antoshenko T; Wang CL; Allali-Hassani A; Dong A; Loppnau P; Vedadi M; Bochkarev A; Sternglanz R; Plotnikov AN
Structure; 2007 Mar; 15(3):377-89. PubMed ID: 17355872
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
[TBL] [Abstract][Full Text] [Related]
19. The Sirtuin family: therapeutic targets to treat diseases of aging.
Milne JC; Denu JM
Curr Opin Chem Biol; 2008 Feb; 12(1):11-7. PubMed ID: 18282481
[TBL] [Abstract][Full Text] [Related]
20. SIRTUIN 1: regulating the regulator.
Zschoernig B; Mahlknecht U
Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
